The analysis showed that semaglutide participants had improvements in cardiovascular risk factors, including waist circumference, a blood sugar metric called HbA1c, total, low-density, and very low-density lipoprotein cholesterol, triglycerides, and liver enzymes compared with the placebo group
Similarly, another smaller study, BEDIP, with a shorter duration, found improvements in a combined neuropathic symptom and sign score after 3 weeks of treatment with 400 mg of benfotiamine daily [72]
He does not read the part that came later: that the foundational papers behind the claim were retracted in 2025 for fabricated data, that the human trials of its drug cousin failed, and that the company built on the science paid the U.S
Genes Dev 2003
The problem with the gallbladder is a real problem
Documented growth hormone and IGF-1 increases The clearest evidence for CJC-1295 comes from its effects on GH and IGF-1 levels